Drug Trial Radar · NCT02729571
Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults
Last checked: Nov 19, 2026Latest source record: May 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Sep 2015
Primary completion
Sep 2016
Study completion Mar 2018
Sponsor
- Lead sponsor
- Biofabri, S.LIndustry
- Sponsor type
- Industry
- Collaborators
- South African Tuberculosis Vaccine Initiative; TuBerculosis Vaccine Initiative; Triclinium Clinical Trial Project Management (Pty) Ltd.; Universidad de Zaragoza
- First posted
- Apr 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 day, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized, controlled, double blind clinical trial in 2 stages (adult stage, infant stage). The first stage includes 18 HIV uninfected, QFT negative, BCG vaccinated, adult participants, randomized 1:1 to receive BCG Vaccine SSI or MTBVAC at equivalent dose (5x10E05 CFU/0.1mL) (n=9 in each group). Upon favourable safety review by the DSMB for all 18 adults up to day 28 after study vaccination, the second stage will commence in thirty-six (36) HIV unexposed, BCG naïve, newborn infants, randomized 1:3 to receive BCG Vaccine SSI or MTBVAC at one of three different dose levels ( (n=9 in each group).
Conditions
- Tuberculosis
Interventions
MTBVACBiological
Live-attenuated tuberculosis vaccine
BCGBiological
Commercially available live-attenuated tuberculosis vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and reactogenicity in infants and adults: includes injection site and systemic and regional adverse events, solicited and unsolicited. A diary card will be for solicited local, regional, and systemic adverse event data.Time frame: Six (6) months post-study vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
South African Tuberculosis Vaccine Initiative, Brewelskloof Hospital
Worcester, Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.